SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company developing human immunoglobulin G (hIgG) therapies for immune and autoimmune disorders. Its platform uses transchromosomic bovine technology to generate disease-targeted polyclonal antibodies, with lead development centered on SAB-142 for autoimmune type 1 diabetes.

−100,0 %

9.46

9.46

— SAB Biotherapeutics, Inc.
%
Lead clinical candidate0% SAB-142 and related development programs targeting autoimmune type 1 diabetes.
Immunotherapy pipeline0% Other hIgG product candidates for immune and autoimmune disorders.
Tc-Bovine antibody platform0% Proprietary transchromosomic cattle platform used to produce disease-targeted hIgG.
Government-funded countermeasure work100% Research and development supported by U.S. government programs and contracts.

SAB Biotherapeutics primarily serves government agencies, clinical investigators, and future commercial patients...

  • Government funding agenciesprimary

    U.S. agencies and programs that fund development, countermeasure, and rapid-response work.

  • Clinical development ecosystemprimary

    Trial sites, investigators, CROs, and collaborators supporting SAB-142 and other studies.

  • Future autoimmune patientsprimary

    Patients with type 1 diabetes and other autoimmune disorders who would use approved therapies.

  • Commercial partnerssecondary

    Potential partners for sales, marketing, and distribution if products reach approval.

The company is headquartered in the United States and conducts its core development and corporate activities from there...

  • •United States is the core operating and funding base
  • •FDA is the primary regulatory pathway for lead programs
  • •UK MHRA and Australian TGA are additional development markets
  • •Specialty animal facilities support Tc-Bovine plasma production
  • •A second facility is being established for redundancy and scale

SAB Biotherapeutics is focused on advancing its lead hIgG programs through clinical development and building the...

01
Advance SAB-142 clinical developmentshort-term

The lead candidate is the main value driver and proof point for the platform.

02
Expand platform into additional autoimmune indicationsmedium-term

A broader indication set can increase the addressable market for the hIgG platform.

03
Increase manufacturing resilience and scalemedium-term

Animal-based plasma production requires capacity, redundancy, and operational control.

04
Prepare for commercialization pathwaysmedium-term

Approval alone is not sufficient without sales, marketing, and distribution execution.

The company faces the typical risks of a clinical-stage biotech: clinical failure, regulatory delay, and the need for...

critical

Financing and going-concern risk

The company expects continued losses and needs external capital to operate.

Scope
Corporate continuity and pipeline funding
Materiality
high
high

Clinical development failure

The company depends on proving SAB-142 and other candidates in human studies.

Scope
Lead candidate and pipeline value
Materiality
high
high

Regulatory approval risk

Product candidates must satisfy FDA and other regulators before commercialization.

Scope
SAB-142 and future autoimmune indications
Materiality
high
medium

Manufacturing and facility dependence

Tc-Bovine plasma production requires specialized animal facilities and redundancy.

Scope
Supply continuity and scale-up
Materiality
medium
medium

Third-party collaboration and data integrity risk

R&D and clinical work rely on CROs, contractors, and external scientific data.

Scope
Trial execution and decision-making
Materiality
medium
Government grant revenue recognition
Affects reported revenue and comparability across periods
Clinical trial and R&D accruals
Affects operating expense timing
Valuation allowance on deferred tax assets
Affects tax provision and equity
Going-concern assessment
Affects liquidity disclosure and investor interpretation

VERU INC.

VERU · Pharmaceutical Preparations

Swedish Orphan Biovitrum

SOBI.ST · Health Care

SYNLOGIC, INC.

SYBX · Pharmaceutical Preparations

Sana Biotechnology, Inc.

SANA · Biological Products, (No Diagnostic Substances)

DYADIC INTERNATIONAL INC

DYAI · Biological Products, (No Diagnostic Substances)

Atara Biotherapeutics, Inc.

ATRA · Biological Products, (No Diagnostic Substances)

: 29.4.2026